21 Apr 2014

Keppra (Levetiracetam) - España

ATC: N03AX
NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
OTHER ANTIEPILEPTICS
Keppra

Last Updated on 21 Apr 2014 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Keppra Indication

Keppra está indicado como monoterapia en el tratamiento de las crisis de inicio parcial con o sin generalización secundaria en adultos y adolescentes de 16 años de edad o mayores con un nuevo diagnóstico de epilepsia.

Keppra está indicado como terapia concomitante
- en el tratamiento de las crisis de inicio parcial con o sin generalización secundaria en adultos, adolescentes, niños y lactantes desde 1 mes de edad con epilepsia.
- en el tratamiento de las crisis mioclónicas en adultos y adolescentes mayores de 12 años con Epilepsia Mioclónica Juvenil.
- en el tratamiento de las crisis tónico-clónicas generalizadas primarias en adultos y adolescentes mayores de 12 años con Epilepsia Generalizada Idiopática.

Keppra Generic Name

Levetiracetam

Type

POM

Summary Product Characteristics (SPCs) Links
Resumen de las Características del Producto - Keppra (external site)

Related Learning Zones

Anti-Coagulation Video Channel

Anti-Coagulation Video Channel

The Anti-Coagulation Video Channel is regularly updated with expert videos discussing how to prevent stroke and systemic embolism in non-valvular atrial fibrillation (AF) patients and how to prevent and treat venous thromboembolism (VTE). This free resource is intended for primary care practitioners and specialists involved in the treatment and follow up care of patients with AF or VTE.

This resource has been developed in collaboration with Boehringer Ingelheim.

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.

This resource has been developed in collaboration with Novartis Pharma AG.

Selected content related to Keppra (Levetiracetam)

News

Guidelines

Back to top